Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3527-3535

  Zhang, Jing Xin ^a   Labaree, David C ^a   Mor, Gil ^a   Hochberg, Richard B ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CARBENE; CHOLESTEROL; ESTER DERIVATIVE; ESTRADIOL DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR BETA; ETHYL (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 11BETA YL)ACETATE; METHYL (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 11BETA YL)ACETATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOASSAY; BREAST CARCINOMA; CANCER PREVENTION; CANCER THERAPY; CELL ASSAY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ESTROGEN ACTIVITY; FEMALE; HORMONE INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; BONE AND BONES; CELL LINE, TUMOR; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; HYDROCARBONS; METHANE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TRANSFECTION; UTERUS;

ANIMALIA;

EID: 3242730057     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032005     Document Type: Article

References (38)

1. Jordan VC 2003 Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. I. Receptor interactions. J Med Chem 46:883-908
2. Jordan VC 2003 Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. II. Clinical considerations and new agents. J Med Chem 46:1081-1111
3. Labaree DC, Reynolds TY, Hochberg RB 2001 Estradiol-16α-carboxylic acid esters as locally active estrogens. J Med Chem 44:1802-1814
4. Labaree DC, Zhang J, Harris HA, O'Connor C, Reynolds TY, Hochberg RB 2003 The synthesis and evaluation of B-, C-, and D-ring substituted estradiol carboxylic acid esters as locally active estrogens. J Med Chem 46:1886-1904
5. 5 adrenal steroids. Endocrinology 127:2757-2762
6. Kuiper GG, Lemmen JG, Carlsson B, Cotton JC, Safe SH, van der Saag PT, Van der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263
7. Mor G, Sapi E, Abrahams VM, Rutherford T, Song J, Hao XY, Muzaffar S, Kohen F 2003 Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol 170:114-122
8. Niwa H, Yamamura K, Miyazaki J 1991 Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199
9. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P 1989 The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8:1981-1986
10. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930
11. Ogawa S, Inoue S, Orimo A, Hosoi T, Ouchi Y, Muramatsu M 1998 Cross-inhibition of both estrogen receptor α and β pathways by each dominant negative mutant. FEBS Lett 423:129-132
12. Emmens CW 1962 Estrogens. In: Dorfman RI, ed. Methods in hormone research. New York: Academic Press; 59-111
13. Baron R, Vignery A, Neff L, Silverglate A, Santa Maria A 1983 Processing of undecalcified bone specimens for bone histomorphometry. In: Recker RR, ed. Bone histomorphometry: techniques and interpretation. Boca Raton, FL: CRC Press
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
15. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
16. Lundeen SG, Carver JM, McKean ML, Winneker RC 1997 Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology 138:1552-1558
17. Marrone BL, Gentry RT, Wade GN 1976 Gonadal hormones and body temperature in rats: effects of estrous cycles, castration and steroid replacement. Physiol Behav 17:419-425
18. Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Makela S, Warner M, Gustafsson JA 2003 Disruption of the estrogen receptor β gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci USA 100:6694-6699
19. Loozen HJJ, Schoonen WGEJ 2000 Estrogenic estra-1,3,5(10)-trienes with differential effects on the α and β estrogen receptors, having a linear hydrocarbon of from 5-9 carbon atoms in position 11. Patent WO 00/31112
20. Bhat KP, Pezzuto JM 2001 Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res 61:6137-6144
21. Shughrue PJ, Lane MV, Merchenthaler I 1999 Biologically active estrogen receptor-β: evidence from in vivo autoradiographic studies with estrogen receptor α-knockout mice. Endocrinology 140:2613-2620
22. Wober J, Weisswange I, Vollmer G 2002 Stimulation of alkaline phosphatase activity in Ishikawa cells induced by various phytoestrogens and synthetic estrogens. J Steroid Biochem Mol Biol 83:227-233
23. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870
24. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA 2000 Pyrazole ligands: structure-affinity/activity relationships and esrrogen receptor-α- selective agonists. J Med Chem 43:4934-4947
25. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA 2001 Estrogen receptor-β potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230-4251
26. Pettersson K, Grandien K, Kuiper GG, Gustafsson JA 1997 Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Mol Endocrinol 11:1486-1496
27. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS 2002 Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand. Endocrinology 143:4172-4177
28. Couse JF, Curtis SW, Washburn TF, Lindzey J, Golding TS, Lubahn DB, Smithies O, Korach KS 1995 Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol 9:1441-1454
29. Wakeling AE, Bowler J 1988 Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645-653
30. Das SK, Taylor JA, Korach KS, Paria BC, Dey SK, Lubahn DB 1997 Estrogenic responses in estrogen receptor-α deficient mice reveal a distinct estrogen signaling pathway. Proc Natl Acad Sci USA 94:12786-12791
31. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL 1980 The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 255:10464-10471
32. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
33. Lajiness M 1991 Evaluation of the performance of dissimilarity performance methodology. In: Silip C, Vitorio A, eds. QSAR: rational approaches to the design of bioactive compounds. Rome: Escom; 201-204
34. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-738
35. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, Gustafsson JA, Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153
36. Pink JJ, Jordan VC 1996 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
37. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA 1999 Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11,12- tetrahydrochrysenes. J Med Chem 42:2456-2468
38. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL 2002 Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364